Sanofi infant vaccine gets EU approval
PARIS, April 22
PARIS, April 22 (Reuters) - French drug maker Sanofi SA said on Monday the European Commission has approved its primary and booster vaccine for infants from six weeks of age.
The vaccine protects infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type B.
The new vaccine will be commercialized by Sanofi Pasteur, the vaccines division of Sanofi, under the brand name Hexyon in Western Europe and Hexacima in Eastern Europe. (Reporting by Astrid Wendlandt; Editing by Daniel Magnowski)
- Ten countries scour sea for Malaysia jet lost in 'unprecedented mystery' |
- Confrontation in Ukraine as diplomacy stalls |
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Mexico kills drug kingpin reported dead years ago: official
- Pistorius vomits in court at Steenkamp autopsy details |